Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $506000.0.

  • Utah Medical Products' Change in Receivables rose 552222.22% to $506000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $626000.0, marking a year-over-year increase of 27041.42%. This contributed to the annual value of $835000.0 for FY2024, which is 13678.41% up from last year.
  • As of Q3 2025, Utah Medical Products' Change in Receivables stood at $506000.0, which was up 552222.22% from -$397000.0 recorded in Q2 2025.
  • Utah Medical Products' 5-year Change in Receivables high stood at $1.2 million for Q3 2022, and its period low was -$1.8 million during Q1 2023.
  • In the last 5 years, Utah Medical Products' Change in Receivables had a median value of $71000.0 in 2021 and averaged $13736.8.
  • The largest annual percentage gain for Utah Medical Products' Change in Receivables in the last 5 years was 552222.22% (2025), contrasted with its biggest fall of 57831.33% (2025).
  • Quarter analysis of 5 years shows Utah Medical Products' Change in Receivables stood at $286000.0 in 2021, then plummeted by 291.61% to -$548000.0 in 2022, then skyrocketed by 75.0% to -$137000.0 in 2023, then surged by 486.13% to $529000.0 in 2024, then fell by 4.35% to $506000.0 in 2025.
  • Its Change in Receivables stands at $506000.0 for Q3 2025, versus -$397000.0 for Q2 2025 and -$12000.0 for Q1 2025.